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Warfarin is the most commonly prescribed oral anticoagulant in sub-Saharan Africa and
requires ongoing monitoring. The burden of both infectious diseases and non-communica-
ble diseases is high and medicines used to treat comorbidities may interact with warfarin.
We describe service provision, patient characteristics, and anticoagulation control at
selected anticoagulation clinics in Uganda and South Africa.
Methods
We evaluated two outpatient anticoagulation services in Kampala, Uganda and three in
Cape Town, South Africa between 1 January and 31 July 2018. We collected information
from key staff members about the clinics’ service provision and extracted demographic and
clinical data from a sample of patients’ clinic records. We calculated time in therapeutic
range (TTR) over the most recent 3-month period using the Rosendaal interpolation
method.
Results
We included three tertiary level, one secondary level and one primary level anticoagulation
service, seeing between 30 and 800 patients per month. Care was rendered by nurses,
medical officers, and specialists. All healthcare facilities had on-site pharmacies; laboratory
INR testing was off-site at two. Three clinics used warfarin dose-adjustment protocols;
these were not validated for local use. We reviewed 229 patient clinical records. Most com-
mon indications for warfarin were venous thrombo-embolism in 112/229 (49%), atrial
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fibrillation in 74/229 (32%) and valvular heart disease in 30/229 (13%). Patients were gener-
ally followed up monthly. HIV prevalence was 20% and 5% at Ugandan and South African
clinics respectively. Cardiovascular comorbidity predominated. Furosemide, paracetamol,
enalapril, simvastatin, and tramadol were the most common concomitant drugs. Anticoagu-
lation control was poor at all included clinics with median TTR of 41% (interquartile range
14% to 69%).
Conclusions
TTR was suboptimal at all included sites, despite frequent patient follow-up. Strategies to
improve INR control in sub-Saharan patients taking warfarin are needed. Locally validated
warfarin dosing algorithms in Uganda and South Africa may improve INR control.
Introduction
Warfarin is the most commonly prescribed oral anticoagulant in resource-limited settings,
where it is used for the treatment and prophylaxis of venous thromboembolism, and for the
prevention of embolic strokes in patients with atrial fibrillation (AF) and valvular heart disease.
Patients receiving warfarin require ongoing monitoring of their International Normalised
Ratio (INR) which needs to be kept in a defined therapeutic range determined by the indica-
tion for therapy. Under-dosing (leading to a sub-therapeutic INR) and overdosing (leading to
a supra-therapeutic INR) places individuals at risk of thrombosis and bleeding, respectively.
INR control in patients in sub-Saharan Africa is often poor [1–3] which may result in poten-
tially preventable morbidity [4] and mortality [5]. The burden of HIV and tuberculosis (TB) is
high in sub-Saharan Africa [6]. Patients on warfarin who are HIV positive and/or have TB
require multiple concomitant medicines, which may interact with warfarin and complicate
warfarin dosing and dose adjustment [7].
In high income countries, warfarin dosing is frequently guided by validated dosing algorithms,
some of which include genotyping for polymorphisms important for warfarin metabolism [8]. Lit-
tle work has been done on validated algorithms to guide dosing in sub-Saharan Africa. Direct oral
anticoagulants (DOACs) are widely accessible in high-income settings, but higher costs limit their
use in resource-limited settings. Warfarin is therefore likely to continue to be used extensively,
and strategies to improve anticoagulation control on warfarin are important.
Our aim was to evaluate the quality of anticoagulation services in Uganda and South Africa
and to describe the clinical and demographic characteristics of patients receiving warfarin.
Materials and methods
Study design and sites
We conducted the audit between 1 January and 31 July 2018. We included two outpatient clin-
ics in Kampala, Uganda: at Mulago National Referral Hospital, and at the Uganda Heart Insti-
tute (UHI), which is a specialized cardiac centre. In South Africa, we included clinics
providing outpatient anticoagulation care at Groote Schuur Hospital, Tygerberg Hospital, and
Gugulethu Community Health Centre. All audited clinics were located in an urban setting. In
Uganda, both clinics were located in referral hospitals where the vast majority of patients
receiving warfarin anticoagulation in the country are managed. The clinics in Cape Town,
South Africa, represented primary, secondary and tertiary levels of care.
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We collected information from key members of clinic staff including doctors, nurses, labo-
ratory and pharmacy staff using a structured data capture sheet. Data collected included avail-
ability and cost of anticoagulation drugs, and INR measurement and availability and use of
dose adjustment protocols (see S1 Data).
We reviewed a sample of patients’ clinic records. The method of sampling clinic records
varied between clinic sites because of difference in systems for record storage and documenta-
tion of clinic attendance. We aimed to minimise sampling bias. However, none of the included
anticoagulation clinics had a readily available sampling frame that included all the patients in
care at that clinic. We therefore could not draw a truly random sample of patients in care at
any of the clinics. We extracted demographic data and clinical data including indication for
anticoagulation, comorbidities, concomitant medications and INR results over the six months
prior to the most recent clinic visit (see S1 Data)
We did not perform a formal sample size calculation as this was a descriptive audit of ser-
vice provision, and as we did not want to test a hypothesis or estimate a parameter with a cer-
tain level of precision. We aimed to review at least 200 clinical records as this was considered
feasible.
Data analysis
Qualitative data were summarised using tables with descriptive text, and quantitative data
expressed as summary statistics–median and interquartile range (IQR). We calculated time in
therapeutic range (TTR) over the most recent three months using the Rosendaal interpolation
method [9]. We did not place any restriction on the maximum interval between INR measure-
ments when applying the method.
We identified concomitant drugs that could interact with warfarin using Stockley’s Drug
Interactions [10].
We used Stata 15.1 (StataCorp, College Station, Texas, USA) and R software package 3.5.3
for statistical analysis and figure generation.
Ethical approvals
The Joint Clinical Research Centre and Uganda National Council for Science and Technology
in Uganda (HS 179ES) and the Human Research Ethics Committee at the Faculty of Health
Sciences of the University of Cape Town in South Africa (585/2017) gave ethics approval. We
obtained institutional clearance for the audited clinics. All staff providing information in
Uganda provided written informed consent prior to participation. In South Africa, the
requirement for written informed consent to be obtained from staff providing information
was waived by the ethics committee.
Results
Anticoagulation services included in this audit are described in Table 1. The number of
patients receiving warfarin ranged from 30 to 800 patients per month. Specialists or medical
doctors were present in all clinics except for the secondary level service in South Africa, which
was staffed by nurses. All facilities had an onsite pharmacy dispensing warfarin. At the Ugan-
dan clinics, warfarin stock outs occurred frequently.
INR turnaround time varied (see Table 1). At health facilities with onsite INR testing,
results were available on the same day. However, for the tertiary hospital in Uganda and the
primary health centre in South Africa, which did not have onsite INR testing services, INR
results were returned the next day, requiring two consecutive visits for the patient. Only one
site (Uganda Heart Institute) had point of care INR testing available.
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At the Ugandan clinics, patients paid approximately £4 for an INR test; occasionally this fee
was subsidised where point of care testing was available. Patients at both Ugandan clinics had
to purchase warfarin themselves when there were drug stock-outs at the clinic; at a cost of
between £3 and £6 for a month’s supply of warfarin depending on warfarin dose. At the South
African clinics, patients did not pay for INR testing or for warfarin.
Three of the included clinics used warfarin dose adjustment protocols. The dose adjustment
protocol used at the Uganda Heart institute was based on the Modified Henry Ford warfarin
maintenance dosing algorithm [11]. The dosing adjustment schedules used in the South Afri-
can clinics were not referenced. To our knowledge these protocols had not been validated for
the clinic population.
We reviewed the clinic records of 229 patients: 68 from Uganda Heart Institute, 32 from
Mulago National Referral Hospital haematology clinic, 48 from Groote Schuur Hospital, 47
from Tygerberg Hospital, and 34 from Gugulethu Community Health Centre. The three most
common indications for warfarin treatment were venous thrombo-embolism (49%), atrial
fibrillation (32%) and valvular heart disease (including mechanical heart valves) (13%). Char-
acteristics of included patients are summarised in Table 2. We found that 126 patients (55%)
had at least one concomitant medication which could potentially interact with warfarin [10].
There were 12 patients (5.2%) on efavirenz and one patient (0.43%) on lopinavir-ritonavir.
TTR was suboptimal at all included sites (see Fig 1). Median TTR overall was 41% (inter-
quartile range 14% to 69%).
Discussion
This evaluation, which included outpatient clinics managing patients on warfarin at primary,
secondary and tertiary level, found that TTR was suboptimal at all included sites. This
occurred despite regular INR monitoring.
Table 1. Characteristics of the five outpatient anticoagulant services in Uganda and South Africa.
UGANDA SOUTH AFRICA
Facility name Mulago National
Referral Hospital






Level of care of clinic/s providing
warfarin
Tertiary Hospital Tertiary Cardiac Centre Secondary Tertiary Primary







Clinic days per week 1 5 4 5� 1
Patients per month 30 400 800 105 113
Onsite pharmacy Yes Yes Yes Yes Yes
DOACs available No Yes (rivaroxaban) No No No
INR turnaround time (days) 1�� 0 ��� 0 0 to 1 2��
INR testing cost to patient per
visit (GBP)
GBP 4 GBP 4 (laboratory INR) GBP 1
(point of care test)
No cost to patient No cost to patient No cost to patient
Frequency of follow-up for
clinically stable patients
Monthly Monthly 4- to 6-weekly Monthly Monthly
Standard protocol used for dose
adjustment
No Yes Yes No Yes
GBP-British Pound Sterling
�There is no dedicated INR clinic. Patients on warfarin are distributed among the specialty clinics depending on where warfarin was initiated and the indication.
��No onsite INR testing services available
���Point-of-care tests available
https://doi.org/10.1371/journal.pone.0227458.t001
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Unfortunately, our findings complement other recent sub-Saharan studies in South Africa,
Namibia and Botswana, all reporting poor INR control, with mean/median TTR ranging from
29% to 47% [1,12,13]. It is known that a higher TTR is associated with increased efficacy of
warfarin and reduction in bleeding complications [14]. In patients with non-valvular AF
receiving warfarin, there is a three-fold risk of ischaemic events with under-anticoagulation
and a five-fold risk of bleeding events with over-anticoagulation, compared to being within the
therapeutic range [14]. Maximising TTR is therefore crucial for attainment of good clinical
outcomes, as shown by a study in the UK, where a 10% increase in time out of range was asso-
ciated with a 29% increased risk of mortality, a 10% increased risk of ischemic stroke, and 12%
increased risk of other thromboembolic events [15].
A number of factors may affect INR control. We found that INR testing was generally avail-
able at all sites; however, patients at the Ugandan clinics had to pay up to £4 for a laboratory
INR test. In addition, frequent pharmacy stock outs of warfarin at these clinics means that
patients also have to incur costs of privately purchasing warfarin. These costs may be prohibi-
tive, particularly in the Ugandan population where the average household monthly income is
Table 2. Characteristics of patients attending five outpatient anticoagulation services in Uganda and South Africa.
Uganda (n = 100) South Africa (n = 129) Overall (n = 229)
Age in years (median [IQR]) 57 [43 to 67] 56 [42 to 65] 56 [43 to 66]
Female (n, (%)) 69 (69%) 87 (67%) 156 (68%)
Indication for warfarin (n, (%))� VTE: 63 (63%) VTE: 49 (38%) VTE: 112 (49%)
AF: 36 (36%) AF: 38 (29%) AF: 74 (32%)
VHD: 1 (1%) VHD: 29 (22%) VHD: 30 (13%)
Other: 0 (0%)�� Other: 17 (13%)�� Other: 17 (7%)��
Number of INR tests in 6 months (median [IQR]) 3 [3 to 4] 5 [3 to 6] 4[3 to 6]
HIV-positive (n, (%)) 20 (20%) 7 (5%) 27 (12%)
Current tuberculosis (n, (%)) 1 (1%) 1 (1%) 2 (1%)
Five most common non-communicable comorbidities (n, (%)) HPT: 29 (29%) HPT: 71 (55%) HPT: 100 (44%)
HF: 10 (10%) DM: 21 (16%) DM: 25 (11%)
HHD: 8 (8%) IHD: 20 (16%) IHD: 23 (10%)
DCMO: 6 (6%) Dyslipidaemia: 19 (15%) HF: 20 (9%)
DM: 4 (4%) HF: 10 (8%) Dyslipidaemia: 19 (7%)
Ten most commonly used concomitant medicines (n, (%)) Furosemide: 43 (43%) Paracetamol: 59 (46%) Furosemide: 90 (39%)
Spironolactone: 21 (21%) Enalapril: 50 (39%) Paracetamol: 59 (26%)
Bisoprolol: 19 (19%) Simvastatin: 49 (38%) Enalapril: 52 (23%)
Digoxin: 16 (16%) Furosemide: 47 (36%) Simvastatin: 50 (22%)
Lamivudine: 15 (15%) Tramadol: 45 (35%) Tramadol: 45 (20%)
Amlodipine:15 (15%) Atenolol: 32 (25%) Amlodipine: 44 (19%)
Telmisartan: 12 (12%) Amlodipine: 29 (22%) Atenolol: 38 (17%)
Sildenafil: 10 (10%) Hydrochlorothiazide: 26 (20%) Hydrochlorothiazide: 35 (15%)
Efavirenz: 9 (9%) Carvedilol: 22 (17%) Spironolactone: 31 (14%)
Hydrochlorothiazide: 9 (9%) Metformin:17 (13%) Carvedilol: 29 (13%)
Zidovudine: 9 (9%)
AF, atrial fibrillation; DCMO, dilated cardiomyopathy; DM, diabetes mellitus; HF, heart failure; HHD, hypertensive heart disease; HPT, hypertension; IHD, ischaemic
heart disease; VHD, valvular heart disease; VTE, venous thrombo-embolism.
� More than one indication may exist; therefore, totals may exceed 100%.
��Other: included chronic venous insufficiency, antiphospholipid syndrome, thrombophilia, congenital heart block and thrombotic syndrome
https://doi.org/10.1371/journal.pone.0227458.t002
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£62 - £144 [16]. However, TTR was poor at South African anticoagulation services as well,
despite patients not having to pay for INR testing or warfarin.
Laboratory turnaround time at two clinics was at least one day requiring a second visit for
dose adjustment, also contributing to increased transport costs and missed work days. Thus,
strengthening laboratory facilities and pharmaceutical supply chain and provision of near-
patient INR testing may contribute to improved anticoagulation control. However, TTR was
poor even at facilities with onsite INR testing and no problems of drug stock outs, suggesting
that there are other factors contributing to poor TTR.
Our population had a high burden of comorbidities such as heart failure and diabetes,
which may be associated with lower TTR [17], because of polypharmacy as well as physiologi-
cal changes due to comorbidity [18]. In addition, high HIV prevalence may further complicate
warfarin dosing due to drug-drug interactions with non-nucleoside reverse transcriptase
inhibitors and protease inhibitors [19,20]. Although our sample included few TB patients, it is
important to consider that rifampicin, which is used in first-line TB treatment, induces warfa-
rin metabolism, which further complicates warfarin dosing [21].
Pharmacogenomic differences due to polymorphisms in VKORC1 and CYP2C9 genes and
additional polymorphisms in other genes e.g. CALU rs339097 may affect dosing requirements
in patients of African descent [22]. Patients managed using genotype guided dosing algorithms
in high-income settings have been shown to have higher mean TTR and fewer episodes of
excessive anticoagulation compared to usual dosing [8]. Further studies need to be conducted
in our population to develop and evaluate clinical and genetic dosing algorithms relevant for
low-income settings.
DOACs require less frequent monitoring and are non-inferior or even superior to warfarin
in preventing stroke in non-valvular AF [23,24]. However, their access is severely limited in
Fig 1. Time in therapeutic INR range (TTR) of patients attending five anticoagulation clinics in Uganda and South Africa (box represents
median and interquartile range).
https://doi.org/10.1371/journal.pone.0227458.g001
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resource-limited settings due to cost limitations; necessitating urgent improvements in warfa-
rin management.
This study has limitations. We only included urban sites, and findings may not be general-
izable to rural settings in South Africa and Uganda. However, in Uganda, we included the clin-
ics known to manage the majority of patients receiving warfarin anticoagulation. It is possible
that there are additional challenges facing anticoagulation services in more remote and poorly
resourced settings in both South Africa and Uganda, which we have not captured. We audited
each included facility at a single timepoint.
In conclusion, in the South African and Ugandan clinics that we evaluated, TTR was subop-
timal. Strategies to improve INR control in sub-Saharan patients taking warfarin are urgently
needed as the alternative DOACs are not freely available. The findings from our work will
inform further research to develop and validate a warfarin dosing algorithm, one such strategy
which may improve TTR, for use in this setting.
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